# Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

> **NCT03641573** · PHASE1 · COMPLETED · sponsor: **Asana BioSciences** · enrollment: 8 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** [14C] ASN002

## Key facts

- **NCT ID:** NCT03641573
- **Lead sponsor:** Asana BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2018-10-21
- **Final completion:** 2018-10-21
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03641573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03641573, "Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03641573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*